← Eichor
Condition: Recurrent Or Metastatic Cervical Cancer Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Recurrent Or Metastatic Cervical Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizuma
Phase 2/Phase 3 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT07554456A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Ca
Phase 3 · 205 location(s) · Merus B.V. · NCT06525220A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell C
Phase 2 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06006169Identification of Individual Histological and Blood Markers in Patients With Recurrent or Metastatic Upper Aerodigestive
NA · 3 location(s) · Fondation Hôpital Saint-Joseph · NCT06061705BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or S
Phase 2 · 225 location(s) · National Cancer Institute (NCI) · NCT05136196Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer
Phase 1/Phase 2 · 1 location(s) · Coordination Pharmaceuticals, Inc. · NCT05838729A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma
Phase 1/Phase 2 · 1 location(s) · West China Hospital · NCT06753747A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard
Phase 2 · 1 location(s) · Shanghai Henlius Biotech · NCT06769113A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC
Phase 2 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT06597565Low-dose Pembrolizumab Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical C
Phase 2 · 1 location(s) · Instituto Nacional de Cancer, Brazil · NCT06670911Impact of Early Response to First-line Anti-PD-1 Monotherapy in Patients With Recurrent and/or Metastatic (R/M) Head and
Phase N/A · 1 location(s) · University of Rome Tor Vergata · NCT07448727A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma
Phase 3 · 1 location(s) · MediLink Therapeutics (Suzhou) Co., Ltd. · NCT06629597Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Tr
Phase 2 · 6 location(s) · Ming-Yuan Chen · NCT07070479A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Meta
Phase 2 · 25 location(s) · Regeneron Pharmaceuticals · NCT06769698Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m
Phase N/A · 1 location(s) · Sun Yat-sen University · NCT06197776A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumor
Phase 1/Phase 2 · 10 location(s) · A2 Biotherapeutics Inc. · NCT06682793Study of TI-0093 Injection With Recurrent/Metastatic HPV-16 Positive Solid Tumors
Phase 1 · 1 location(s) · Therorna · NCT07081984Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06657690Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Meta
Phase 2 · 88 location(s) · National Cancer Institute (NCI) · NCT06029270A Phase I/II Trial of HCB101 in Combination With Pembrolizumab for Patients With Platinum-Refractory, Recurrent or Metas
Phase 1/Phase 2 · 3 location(s) · Taipei Veterans General Hospital, Taiwan · NCT07136545A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
Phase 1/Phase 2 · 20 location(s) · MediLink Therapeutics (Suzhou) Co., Ltd. · NCT07258979Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Phase 1 · 30 location(s) · Calico Life Sciences LLC · NCT04777994Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma
Phase 1/Phase 2 · 17 location(s) · Nykode Therapeutics ASA · NCT06016920A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gyn
Phase 2 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT05990803Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer
Phase 1/Phase 2 · 30 location(s) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · NCT07367516A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance
Phase 2 · 15 location(s) · Shanghai Henlius Biotech · NCT06839066SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer
Phase 1/Phase 2 · 1 location(s) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · NCT06859775Intratumoral Injection of Recombinant Human Endostatin Adenovirus (EDS01) for the Treatment of Recurrent or Metastatic H
Phase 1 · 1 location(s) · West China Hospital · NCT07625423Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
Phase 4 · 129 location(s) · Pfizer · NCT06952660Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer
Phase 3 · 5 location(s) · Lee's Pharmaceutical Limited · NCT06459687
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.